alalevonadifloxacin

Alalevonadifloxacin is a DNA gyrase and DNA topoisomerase inhibitor and a novel antibacterial compound of the quinolone class targeting MRSa. Alalevonadifloxacin is potentially useful in the treatment of bacterial Gram-positive, Gram-negative and anaerobic infections.

Alalevonadifloxacin HCl is a novel l-alanine ester prodrug of levonadifloxacin.

Alalevonadifloxacin (WCK-2349) mesylate is an orally active antibiotic targeting both Gram-positive and Gram-negative bacteria. Alalevonadifloxacin mesylate shows potential for research in treating acute bacterial skin and skin structure infections, as well as hospital-acquired pneumonia caused by MRSA and other pathogens.